Back to top

Anti-Kickback Statute Webinar

Event Date: 
Wednesday, March 25, 2020
1:00 PM - 2:00 PM
Registration Fee: 
Complimentary (DTA Member Exclusive)

Understanding and Mitigating Anti-Kickback Risk for Dental Companies

In this webinar, Ed Buthusiem and Brian Hoyt of Berkeley Research Group will explore the origins and application of the Anti-kickback statutes to the Dental Industry, including interactions with dental practitioners and other dental providers and teaching hospitals and how such activities are regulated by the anti-kickback laws and regulations. The session will also describe ways in which anti-kickback risk can be tracked and mitigated through the use of advanced data analytics.

Who should register?

  • Manufacturers that sell directly to or have relationships with dentists and other dental office decision-makers.
  • Dental laboratories.
  • Distributors who deal directly with dentists and other dental practitioners.
  • Key staff working with regulatory compliance.

Register Now!

About the Presenters: 

Edward J. Buthusiem

Mr. Buthusiem is a Managing Director in the BRG Health Analytics practice and a leader of its Corporate Compliance and Risk Management practice. He has over 30 years of experience advising clients on a variety of business, regulatory, operational, intellectual property, litigation, transactional and compliance matters, with particular emphasis in pharmaceutical and medical device product and technology licensing transactions, commercial and strategic transactions, business formation and planning, securities, mergers and acquisitions, compliance, and corporate governance. Since joining BRG in 2013, Mr. Buthusiem has provided expert testimony and support in a number of litigation matters involving, among other things, the interpretation of licensing and development contracts relating to pharmaceutical and medical device product development, deal structures, valuation and pricing, matters involving fiduciary responsibilities, securities disclosure, adequacy of internal controls and pharmaceutical pre-clinical and clinical development and commercialization.

Mr. Buthusiem has served as a government and court-appointed monitor for entities subject to post-settlement and post-acquisition mandates, including on behalf of the US Department of Justice (DOJ), the Securities and Exchange Commission (SEC) and the Office of Inspector General (OIG) in connection with various civil and criminal actions. Mr. Buthusiem has also served as a court-appointed monitor in connection with the disposition of assets in bankruptcy proceedings as well as an independent third party to oversee the implementation of post-closing obligations primarily involving M&A transactions. He has advised healthcare companies and their legal counsel in implementing Corporate Integrity Agreements (CIAs), as well as negotiating CIA terms with the Department of Justice, the OIG, the SEC, and other governmental agencies. Mr. Buthusiem has also developed and overseen all aspects of compliance programs, including auditing and monitoring; interactions and engagements with healthcare professionals; determining fair market value of goods and services provided by and offered to physicians; strategic marketing and sales initiatives; transparency reporting; and clinical, research and development, and post-market surveillance.

Person Category: